HLUKF News and Press, H Lundbeck A/S From 11/05/19

The following slide deck was published by H. Lundbeck A/S in conjunction with their 2019 Q3 earnings Read more ...

H. Lundbeck A/S ( OTC:HLUKF ): 9M Non-GAAP EPS of DKK15.40; GAAP EPS of DKK12.27. More news on: H. Lundbeck A/S, H. Lundbeck A/S, Earnings news and commentary, Healthcare stocks news, Read more ...

Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...

H. Lundbeck A/S ( OTC:HLUKF ) has agreed to acquire Alder BioPharmaceuticals (NASDAQ: ALDR ) for $18 per share in cash plus one non-tradeable Contingent Value Right (CVR) for an additional $2 per share if migraine med eptinezumab is approved by the European Medicines Agency (EMA). The total ...

H. Lundbeck A/S (HLUKF) Q2 2019 Earnings Conference Call August 14, 2019 7:00 AM ET Company Participants Deborah Dunsire - President & Chief Executive Officer Anders Götzsche - Executive Vice President & Chief Financial Officer Johan Luthman - Head of Research & ...

The following slide deck was published by H. Lundbeck A/S in conjunction with their 2019 Q2 earnings Read more ...

H. Lundbeck A/S ( OTC:HLUKF ): Q2 GAAP EPS of DKK3.96. More news on: H. Lundbeck A/S, H. Lundbeck A/S, Earnings news and commentary, Healthcare stocks news, Read more ...

Denmark’s H. Lundbeck ( OTC:HLUKF ) snaps up Abide Therapeutics and adds differentiated chemo-proteomic discovery platform and a US-based research hub. More news on: H. Lundbeck A/S, H. Lundbeck A/S, Healthcare stocks news, Merger & acquisition news, Read more ...

With one candidate at Phase 3 of development, Trevi Therapeutics ( TRVI ) should interest IPO investors. Besides, the market will probably like the massive market opportunity. The total market for pruritus therapeutics was $11.09 billion in 2018. With that, it is not ideal that the company exp...

Minerva Neurosciences ( NERV ) is set to report data from multiple clinical trials in 2019 but roluperidone, which NERV is developing as a treatment for the negative symptoms of schizophrenia, is likely to get a disproportionate amount of attention. NERV and others developing in the negative...